MITF and melanoma: Interestingly, since MITF pathway activation and BRAF mutations, leading to MAPK signaling activation, occur, respectively, in about 10–20% (30) and 50% (31) of melanomas, it is possible to assume that the constitutive expression of HIF-1α is not a rare event in melanoma (32) and strictly correlates with melanoma aggressiveness and malignancy (23).